Literature DB >> 28295225

The association between systemic lupus erythematosus and valvular heart disease: an extensive data analysis.

Abdulla Watad1,2,3, Shmuel Tiosano1,3, Noam Grysman3, Doron Comaneshter4, Arnon D Cohen4,5, Yehuda Shoenfeld2,3, Howard Amital1,2,3.   

Abstract

BACKGROUND: Association between antiphospholipid syndrome in systemic lupus erythematosus (SLE) and valvular heart disease (VHD) is well reported, but relatively few studies have been carried out to establish the linkage between VHD and SLE itself. We aimed to investigate link between VHD and SLE and to evaluate the association of diverse factors with VHD among these patients in a large-scale population-based study.
MATERIALS AND METHODS: We used the databases of the largest state-mandated health service organization in Israel. All SLE patients were included (n = 5018) as well as their age and sex-matched controls (n = 25 090), creating a cross-sectional population-based study. Medical records of all subjects were analysed for documented VHD and the presence of antiphospholipid antibodies (aPLs). A logistic regression model was carried out to evaluate the diverse factors including SLE and aPLs as independent risk factors for VHD.
RESULTS: Valvular heart disease were found to be more frequent among SLE group when compared to controls (aortic stenosis, 1·08% vs. 0·35% respectively, P < 0·001; aortic insufficiency, 1·32% vs. 0·29% respectively, P < 0·001; mitral stenosis, 0·74% vs. 0·21% respectively, P < 0·001; mitral insufficiency, 1·91% vs. 0·39% respectively, P < 0·001). Male sex, hypertension, aPLs and SLE were found to be significant independent risk factors for VHD.
CONCLUSION: All VHD are more prevalent among SLE patients when compared to controls. SLE and aPLs are independent risk factor for VHD (OR of 2·46 and 1·7, respectively). Physicians must be aware of such significant association, and routine echocardiography should be considered in SLE patients regardless of their aPL status.
© 2017 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  Antiphospholipids antibodies; Libman-Sacks; lupus; mitral insufficiency; systemic lupus erythematosus; valve heart disease

Mesh:

Substances:

Year:  2017        PMID: 28295225     DOI: 10.1111/eci.12744

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival.

Authors:  Abdulla Watad; Dennis McGonagle; Nicola L Bragazzi; Shmuel Tiosano; Doron Comaneshter; Yehuda Shoenfeld; Arnon D Cohen; Howard Amital
Journal:  Oncoimmunology       Date:  2019-03-24       Impact factor: 8.110

Review 2.  Assessment of Cardiac Risk in Women with Autoimmune Disease.

Authors:  Tyler Schmidt; Rekha Mankad
Journal:  Curr Cardiol Rep       Date:  2022-05-07       Impact factor: 3.955

Review 3.  Disorders of the Aorta and Aortic Valve in Connective Tissue Diseases.

Authors:  Bogna Grygiel-Górniak; Mary-Tiffany Oduah; Abdulbaril Olagunju; Michal Klokner
Journal:  Curr Cardiol Rep       Date:  2020-06-19       Impact factor: 2.931

4.  Autoimmune connective tissue diseases and aortic valve replacement outcomes: a population-based study.

Authors:  Mohamed M Gad; Devora Lichtman; Anas M Saad; Toshiaki Isogai; Agam Bansal; Mouin S Abdallah; Eric Roselli; Soumya Chatterjee; Grant W Reed; Samir R Kapadia; Venu Menon; Heba Wassif
Journal:  Eur Heart J Open       Date:  2022-04-06

Review 5.  Cardiac Calcifications: Phenotypes, Mechanisms, Clinical and Prognostic Implications.

Authors:  Francesco Vieceli Dalla Sega; Francesca Fortini; Paolo Severi; Paola Rizzo; Iija Gardi; Paolo Cimaglia; Claudio Rapezzi; Luigi Tavazzi; Roberto Ferrari
Journal:  Biology (Basel)       Date:  2022-03-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.